ABSTRACT
Copper is indispensable for various metabolic processes, notably mitochondrial respiration. In humans, copper homeostasis hinges on transporters such as copper transporter 1 (CTR1), encoded by the SLC31A1 gene. Recently, bi-allelic mutations in SLC31A1 have been associated with a new neurodevelopmental disorder. This study presents clinical, genetic, and biochemical findings from 13 new cases across 10 families worldwide. RNA sequencing evaluated gene expression, and Western blotting assessed CTR1 protein levels. Additionally, mitochondrial respiratory capacity was measured via high-resolution respirometry. Affected individuals exhibited a distinct clinical phenotype characterized by early-onset epileptic encephalopathy, severe neurodevelopmental delay and hypotonia, with high mortality. Neuroimaging revealed significant brain atrophy and white matter abnormalities. Genetic analysis identified bi-allelic SLC31A1 variants, predominantly p.His120Gln in six cases and p.(Arg102Cys/His) in three cases. Functional studies in patient fibroblasts demonstrated impaired mitochondrial respiration. This study significantly broadens the clinical spectrum of this recently described syndrome, presenting as a severe developmental encephalopathy with high mortality risk, and suggests mitochondrial dysfunction as a potential pathomechanism. These findings contribute to the mounting evidence linking CTR1 dysfunction to neurodegeneration, underscoring the urgency for further therapeutic investigations.
Competing Interest Statement
EZ, PB and ABA are employed by CENTOGENE GmbH. The remaining authors declare no conflict of interest.
Funding Statement
This research was supported by the projects PI19/01310, PI20/00340, and PI22/00856, PI20-00541, funded by the Instituto de Salud Carlos III and co-funded by the European Union. The study was supported by the Departament de Salut de la Generalitat de Catalunya (PERIS: SLT002/16/00174) and the Agencia de Gestio d Ajuts Universitaris i de Recerca (AGAUR) (2021:SGR 01423), GENOMIT-4 (EJPRD22-123) and the CERCA Programe/Generalitat de Catalunya. AJPF held grants from the Instituto de Salud Carlos III, Spain (FI18/00253), and from the Asociacion de Enfermos de Patologias Mitocondriales (AEPMI)/Fundacion Ana Carolina Diez Mahou, Spain.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the ethical committees of each institution and is in accordance with the Helsinki Declaration of 1964, as revised in 2001. The study was approved by the HSJD ethics committee with the reference number PIC-97-16.s. Family 4 was enrolled in a research protocol approved by the Institutional Review Board at the Icahn School of Medicine at Mount Sinai, Family 5 was enrolled in the Solve-RD-solving the unsolved rare diseases program by the European Commission and Family 6 was part of the URDCat program. Adult participants and guardians of children provided written informed consent for participation
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data availability
The data that support the findings of this study are available on a reasonable request to the corresponding author and patient caregivers. The data are not publicly available due to privacy and ethical restrictions.
